OMRON-HEALTHCARE
OMRON Healthcare , Inc., the global leader in remote blood pressure monitoring and personal health technology, spotlighted its new remote patient monitoring services at the 2022 Consumer Electronics Show (CES) and won “Best of” honors for its offerings in the U.K. and U.S:
- Hypertension Plus by OMRON in the U.K. was selected as a TWICE Picks Awards winner for the 2022 TWICE , Residential Systems and TechRadar Pro Picks Awards
- VitalSight™ by OMRON in the U.S. was recognised as an INSIDER “Best of” CES selection
These remote patient monitoring services gained recognition at the world’s largest innovation show as breakthrough health technology designed to foster greater active health condition management, strengthen the patient-physician connection, and guide behavior change to reduce health risks, while advancing the company’s mission of Going for Zero heart attacks and strokes.
“OMRON developed Hypertension Plus as the first step toward transforming chronic care in the U.K., while VitalSight was designed to help the 37 million Americans who have uncontrolled Stage 2 hypertension and live every day with a higher risk of heart attack and stroke,” said Andre Van Gils, senior general manager, global sales & marketing and executive officer of OMRON Healthcare Corporation Ltd. - Japan.
Hypertension Plus is designed to help NHS clinicians manage a patient’s medication plan remotely, based on the patient’s home blood pressure results submitted through its dedicated mobile app. The platform generates tailored medication plans for patients, which are then adjusted by clinicians as necessary. Patients are then informed immediately over the dedicated mobile app, connecting them directly to their physician. Automated reminders and scheduled condition management actions keep the patient engaged in treatment. Over time, Hypertension Plus collates the patient’s blood pressure readings along with other key health parameters and informs clinicians when it’s time for their patients to progress in their treatment plan or if there is any urgent action to be taken. All of these recommendations are underpinned by an exclusive algorithm founded on clinically proven medication titration techniques for hypertension, based on current National Institute for Health and Care Excellence (NICE) guidelines, and developed by Oxford university.
In addition to CES, Hypertension Plus has also been recognised by ORCHA (the Organisation for the Review of Care and Health Applications) and Dorset Clinical Commission Group (CCG) on their leading UK-recognised health and care app review portal, with Hypertension Plus currently the highest rated application for hypertension.
In their annual rankings, TWICE, Residential Systems , and TechRadar Pro Picks Awards honor the best and most influential consumer technology. The TWICE Picks Awards Winners 2022 were chosen based on the impact that they are expected to have on the consumer electronic and retail Industries. To see the full list, visit TWICE , Residential Systems or TechRadar Pro .
VitalSight is the first remote patient monitoring service from OMRON Healthcare, an easy-to-use service that a physician can offer to patients with high-risk levels of hypertension. Patients receive a kit delivered to their home that includes an OMRON connected blood pressure monitor and data hub that are pre-set to securely share measurements – digitally – with the patient’s physician and care team. The VitalSight data hub, which can be used at home without Wi-Fi or cellular connection, received attention at CES for bridging health care gaps for patients in under-resourced communities.
Insider recognised VitalSight by OMRON on its list of 13 most exciting health, home and kitchen products of CES 2022. The list brought together high-tech concepts and new products – unveiled at CES 2022 – that you can buy now or later in 2022. Insider cited VitalSight among the “Best of” CES as “life-saving technology” and “great technology for patients who can't see their doctor regularly because of location, finances, or mobility concerns.” To see the full list, visit Insider.
“Our team, fully committed to our Going for Zero mission, worked diligently to create and launch our remote patient monitoring services around the world,” said Van Gils. “We are fortunate to have such dedicated staff and employees who are passionate about empowering people to take charge of their heart health and saving lives. Congratulations to our team on this extraordinary effort.”
To learn more about Remote Patient Monitoring services from OMRON, visit: https://healthcare.omron.com/ces2022
To learn more about OMRON Healthcare, the company’s Going for Zero mission and its innovations, visit omron-healthcare.co.uk , and follow OMRON Healthcare on Twitter and LinkedIn.
About OMRON Healthcare
Committed to helping people live more active and fulfilling lives with zero compromise, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy.
Throughout its 85-year history OMRON Healthcare has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in over 117 countries.
OMRON Healthcare is the Global No.1 brand in both blood pressure monitors, with over 200 million units sold, as well as nebulizers for respiratory treatment with over 30 million devices sold. The company’s additional core product categories are low-frequency pain therapy equipment, body composition monitors and electronic thermometers.
OMRON Healthcare Group is headquartered in Kyoto, Japan. OMRON Healthcare Europe B.V. is the healthcare division for Europe, Russia, Middle East and Africa and provides services to customers in more than 74 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220121005268/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vedanta Resources Launches CopperTech Metals to Bolster U.S. Copper Security and Advance Technology and Infrastructure Transformation6.11.2025 17:45:00 CET | Press release
CopperTech Metals Combines World-Class Konkola Mines' Copper and Cobalt Producing Heritage with Cutting-Edge Mining Technology and Artificial Intelligence to Advance U.S. Critical Mineral Independence and Serve America's Growing Infrastructure Needs$1.5 Billion Investment Program to Leverage Advanced Mining and Cutting-Edge AI-Driven Resource Identification and Extraction Technology to Propel Konkola's Operations into One of the Largest in the World Vedanta Resources Limited ("Vedanta") today announced the launch of CopperTech Metals Inc. ("CopperTech" or the "Company"), a U.S.-domiciled company with a mission to 'Power the Copper Century' and to bolster America's copper security needs while capitalizing on surging copper demand driven by artificial intelligence, data center expansion, grid modernization, defense technologies and industrial onshoring requirements. CopperTech will1 own and operate the Konkola Copper Mines in Zambia, one of the highest-grade copper producing assets in th
NJ Bio Bridges the Translation Research Gap with the Asset Purchase and Integration of L2P®Services6.11.2025 17:11:00 CET | Press release
NJ Bio, Inc., a premier contract research and clinical manufacturing service provider in Princeton, New Jersey has announced the asset purchase and full integration of the research services of L2P Research Labs® (“Lab to Pharmacy”), further expanding its service portfolio, and bridging the translational research gap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251106703527/en/ NJ Bio, Inc. now offers translational research services after completing asset purchase and full integration of the services of L2P® Research Labs, enhancing the discovery-to-development pipeline Currently, the attrition rate of biological molecules moving past phase 1 clinical trials is very high and the way to overcome this challenge is through translational research. NJ Bio specializes in preclinical and early-phase clinical research and development, with a primary focus on ADCs, bioconjugation, custom synthesis, oligonucleotides, and mRNAs. Howe
DevvStream Reports Fiscal Year 2025 Results and Advances Digital-Asset and Tokenization Strategy6.11.2025 17:01:00 CET | Press release
Company strengthens balance sheet, launches disciplined digital-asset treasury, and sets stage for acquisition-led growth in sustainability markets DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management and environmental-asset monetization firm, today announced financial results for its fiscal year ended July 31, 2025, and provided an update on strategic initiatives designed to enhance liquidity, expand technology capabilities, and position the Company for scalable, acquisition-driven growth. Fiscal 2025 Highlights Completed Nasdaq listing and de-SPAC transaction, establishing DevvStream as one of the few publicly traded pure plays in carbon and renewable-energy asset monetization. Closed initial $10 million tranche under the Helena $300 million convertible-note facility, providing liquidity to launch the Company’s digital-asset treasury. Reported initial revenue as the Company begins monetizing its environmental-asset pipeline. Successfully comple
BST Global Launches 2026 AI + Data Impact Survey for the AEC Industry6.11.2025 16:41:00 CET | Press release
BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its second annual global AI + Data Survey. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105615222/en/ BST Global, the leading provider of AI-powered project intelligence™ solutions for the AEC industry, has launched its second annual global AI + Data Survey. Seeking insights from technology and data leaders of architecture, engineering and environmental consultancies around the world, the survey will be available until 11:59 p.m. ET, December 31, 2025. Conducted in partnership with BST Global’s AI + Data Consortium and the American Council of Engineering Companies' (ACEC) Technology Committee, the survey focuses s
Scientist.com Wins Supplier Management Excellence Award at B2B Ecommerce Awards6.11.2025 15:43:00 CET | Press release
AI-enabled R&D orchestration platform honored for innovation and leadership in supplier integration and governance Scientist.com, the leading AI-enabled R&D orchestration platform for the life sciences, has been named the winner of the Supplier Management Excellence award at the prestigious B2B Ecommerce Awards. The honor recognizes organizations that set new standards in supplier network innovation, integration, and performance to deliver superior customer value. “Winning this award is a tremendous honor and a testament to our team’s relentless focus on simplifying and accelerating R&D,” said Andrew Nashed, VP, Supplier Relations at Scientist.com. “Our platform automates and optimizes the complex process of supplier management, enabling scientists to focus on innovation while we handle compliance, integration, and operational efficiency.” Scientist.com was recognized for its industry-leading approach to building and managing the world’s largest network of scientific service providers.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
